Efficacy of a recombinant rift valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep

Hana M. Weingartl, Charles K. Nfon, Shunzhen Zhang, Peter Marszal, William C. Wilson, John C. Morrill, George E. Bettinger, Clarence J. Peters

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Rift Valley fever virus (RVFV), a mosquito-borne virus in the Bunyaviridae family and Phlebovirus genus, causes RVF, a disease of ruminants and man, endemic in Sub-Saharan African countries. However, outbreaks in Yemen and Saudi Arabia demonstrate the ability for RVFV to spread into virgin territory and thus the need exists to develop safe and efficacious vaccines that can be used outside the endemic zones. Commercial RVFV vaccines are available but have limitations that prevent their use in disease-free countries. Consequently, there are ongoing efforts to develop and/or improve RVFV vaccines with global acceptability. In this study a previously developed MP-12-derived vaccine candidate with a large deletion of the NSm gene in the pre Gn region of the M segment (arMP-12-δNSm21/384) developed by T. Ikegami, that was already shown to be safe in pregnant sheep causing neither abortion nor fetal malformation was further evaluated. This vaccine was tested for protection of sheep from viremia and fever following challenge with virulent RVFV ZH501 strain. A single vaccination with arMP-12-δNSm21/384 fully protected sheep when challenged four weeks post vaccination, thereby demonstrating that this vaccine is efficacious in protecting these animals from RVFV infection.

Original languageEnglish (US)
Pages (from-to)2345-2349
Number of pages5
JournalVaccine
Volume32
Issue number20
DOIs
StatePublished - Apr 25 2014

Fingerprint

Rift Valley fever virus
Sheep
Vaccines
vaccines
sheep
Phlebovirus
Vaccination
Bunyaviridae
vaccination
Yemen
abortion (animals)
Saudi Arabia
gene deletion
Viremia
viremia
Gene Deletion
Ruminants
Virus Diseases
Culicidae
fever

Keywords

  • NSm deleted MP-12
  • Rift Valley fever
  • Sheep
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Weingartl, H. M., Nfon, C. K., Zhang, S., Marszal, P., Wilson, W. C., Morrill, J. C., ... Peters, C. J. (2014). Efficacy of a recombinant rift valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep. Vaccine, 32(20), 2345-2349. https://doi.org/10.1016/j.vaccine.2013.12.064

Efficacy of a recombinant rift valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep. / Weingartl, Hana M.; Nfon, Charles K.; Zhang, Shunzhen; Marszal, Peter; Wilson, William C.; Morrill, John C.; Bettinger, George E.; Peters, Clarence J.

In: Vaccine, Vol. 32, No. 20, 25.04.2014, p. 2345-2349.

Research output: Contribution to journalArticle

Weingartl, HM, Nfon, CK, Zhang, S, Marszal, P, Wilson, WC, Morrill, JC, Bettinger, GE & Peters, CJ 2014, 'Efficacy of a recombinant rift valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep', Vaccine, vol. 32, no. 20, pp. 2345-2349. https://doi.org/10.1016/j.vaccine.2013.12.064
Weingartl HM, Nfon CK, Zhang S, Marszal P, Wilson WC, Morrill JC et al. Efficacy of a recombinant rift valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep. Vaccine. 2014 Apr 25;32(20):2345-2349. https://doi.org/10.1016/j.vaccine.2013.12.064
Weingartl, Hana M. ; Nfon, Charles K. ; Zhang, Shunzhen ; Marszal, Peter ; Wilson, William C. ; Morrill, John C. ; Bettinger, George E. ; Peters, Clarence J. / Efficacy of a recombinant rift valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep. In: Vaccine. 2014 ; Vol. 32, No. 20. pp. 2345-2349.
@article{a7a16144afe14f3987db2791caa4554b,
title = "Efficacy of a recombinant rift valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep",
abstract = "Rift Valley fever virus (RVFV), a mosquito-borne virus in the Bunyaviridae family and Phlebovirus genus, causes RVF, a disease of ruminants and man, endemic in Sub-Saharan African countries. However, outbreaks in Yemen and Saudi Arabia demonstrate the ability for RVFV to spread into virgin territory and thus the need exists to develop safe and efficacious vaccines that can be used outside the endemic zones. Commercial RVFV vaccines are available but have limitations that prevent their use in disease-free countries. Consequently, there are ongoing efforts to develop and/or improve RVFV vaccines with global acceptability. In this study a previously developed MP-12-derived vaccine candidate with a large deletion of the NSm gene in the pre Gn region of the M segment (arMP-12-δNSm21/384) developed by T. Ikegami, that was already shown to be safe in pregnant sheep causing neither abortion nor fetal malformation was further evaluated. This vaccine was tested for protection of sheep from viremia and fever following challenge with virulent RVFV ZH501 strain. A single vaccination with arMP-12-δNSm21/384 fully protected sheep when challenged four weeks post vaccination, thereby demonstrating that this vaccine is efficacious in protecting these animals from RVFV infection.",
keywords = "NSm deleted MP-12, Rift Valley fever, Sheep, Vaccine",
author = "Weingartl, {Hana M.} and Nfon, {Charles K.} and Shunzhen Zhang and Peter Marszal and Wilson, {William C.} and Morrill, {John C.} and Bettinger, {George E.} and Peters, {Clarence J.}",
year = "2014",
month = "4",
day = "25",
doi = "10.1016/j.vaccine.2013.12.064",
language = "English (US)",
volume = "32",
pages = "2345--2349",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "20",

}

TY - JOUR

T1 - Efficacy of a recombinant rift valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep

AU - Weingartl, Hana M.

AU - Nfon, Charles K.

AU - Zhang, Shunzhen

AU - Marszal, Peter

AU - Wilson, William C.

AU - Morrill, John C.

AU - Bettinger, George E.

AU - Peters, Clarence J.

PY - 2014/4/25

Y1 - 2014/4/25

N2 - Rift Valley fever virus (RVFV), a mosquito-borne virus in the Bunyaviridae family and Phlebovirus genus, causes RVF, a disease of ruminants and man, endemic in Sub-Saharan African countries. However, outbreaks in Yemen and Saudi Arabia demonstrate the ability for RVFV to spread into virgin territory and thus the need exists to develop safe and efficacious vaccines that can be used outside the endemic zones. Commercial RVFV vaccines are available but have limitations that prevent their use in disease-free countries. Consequently, there are ongoing efforts to develop and/or improve RVFV vaccines with global acceptability. In this study a previously developed MP-12-derived vaccine candidate with a large deletion of the NSm gene in the pre Gn region of the M segment (arMP-12-δNSm21/384) developed by T. Ikegami, that was already shown to be safe in pregnant sheep causing neither abortion nor fetal malformation was further evaluated. This vaccine was tested for protection of sheep from viremia and fever following challenge with virulent RVFV ZH501 strain. A single vaccination with arMP-12-δNSm21/384 fully protected sheep when challenged four weeks post vaccination, thereby demonstrating that this vaccine is efficacious in protecting these animals from RVFV infection.

AB - Rift Valley fever virus (RVFV), a mosquito-borne virus in the Bunyaviridae family and Phlebovirus genus, causes RVF, a disease of ruminants and man, endemic in Sub-Saharan African countries. However, outbreaks in Yemen and Saudi Arabia demonstrate the ability for RVFV to spread into virgin territory and thus the need exists to develop safe and efficacious vaccines that can be used outside the endemic zones. Commercial RVFV vaccines are available but have limitations that prevent their use in disease-free countries. Consequently, there are ongoing efforts to develop and/or improve RVFV vaccines with global acceptability. In this study a previously developed MP-12-derived vaccine candidate with a large deletion of the NSm gene in the pre Gn region of the M segment (arMP-12-δNSm21/384) developed by T. Ikegami, that was already shown to be safe in pregnant sheep causing neither abortion nor fetal malformation was further evaluated. This vaccine was tested for protection of sheep from viremia and fever following challenge with virulent RVFV ZH501 strain. A single vaccination with arMP-12-δNSm21/384 fully protected sheep when challenged four weeks post vaccination, thereby demonstrating that this vaccine is efficacious in protecting these animals from RVFV infection.

KW - NSm deleted MP-12

KW - Rift Valley fever

KW - Sheep

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84897562603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897562603&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2013.12.064

DO - 10.1016/j.vaccine.2013.12.064

M3 - Article

C2 - 24462482

AN - SCOPUS:84897562603

VL - 32

SP - 2345

EP - 2349

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 20

ER -